Corcept Therapeutics presented positive results from its Phase 3 long-term, open-label extension study of relacorilant for endogenous hypercortisolism (Cushing's syndrome). The study demonstrated that patients treated with relacorilant experienced clinically meaningful and durable cardiometabolic improvements over a treatment duration of up to six years.
Patients in the study showed further reductions in blood pressure and maintained improvements in other cardiometabolic measures, such as glycemic control and body weight. At month 24, patients exhibited statistically significant reductions in mean systolic blood pressure (10.0 mm Hg; p-value: 0.012) and mean diastolic blood pressure (7.3 mm Hg; p-value: 0.016) compared to entry into the study.
Relacorilant was well-tolerated throughout the extended treatment period, with a safety profile consistent with previous trials. Importantly, there were no instances of drug-induced adrenal insufficiency, hypokalemia, QT prolongation, or progesterone receptor-mediated adverse events, which are serious concerns with other treatments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.